Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
Added By: Feedage Forager Feedage Grade B rated
Language: English
cannabis  clinical  company  marketwired oct  marketwired october  marketwired  new  oct  october  patient  today  toronto marketwired 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials

Marketwired - Trials

Last Build Date: Mon, 24 Oct 2016 03:34:29 EDT

Copyright: Copyright: (C) Marketwired

Dr. Gearoid Tuohy joins Cromos(TM) Pharma as VP, International Business and Operations; Company plans to expand its operations

Mon, 24 Oct 2016 02:36:32 EDT

DUBLIN, IRELAND--(Marketwired - October 24, 2016) - CromosT Pharma, a premier regional contract research organization announced today that Dr. Gearóid Tuohy has been appointed as Vice President, International Business and Operations. Dr. Tuohy will join the company's Dublin office and will bring strategic thinking and in-depth knowledge of the international clinical trials landscape to further expand CromosT Pharma's operations amidst its growing geographic presence. "CromosT Pharma continues to grow at a fast pace and we are very excited to see Dr. Tuohy joining our team," said Dr. Vlad Bogin, CromosT Pharma's CEO. "We have made significant progress in expanding our operations and attracting clients that look for expeditious, cost-efficient and high quality clinical research. With the addition of Dr. Tuohy we are positioning the company to bring high-value solutions to new and existing clients," Dr. Bogin continued.

eWellness Announces Its Commercial Launch of its PHZIO Telemedicine Platform

Fri, 21 Oct 2016 16:58:43 EDT

CULVER CITY, CA--(Marketwired - Oct 21, 2016) -  eWellness Healthcare Corporation, (OTCQB: EWLL) is the first physical therapy ("PT") telemedicine company to offer insurance reimbursable real-time distance monitored physical therapy treatments. The Company is pleased to announce that it successfully held its commercial launch of its PHZIO PT telemedicine intervention system as a Tier 1 sponsor of the American Physical Therapy Association ("APTA"), Private Practice Section (PPS) Annual Conference held in Las Vegas.

Cannabis Science Announces Products Hitting Shelves in Legal Dispensaries in the State of California

Fri, 21 Oct 2016 11:09:29 EDT

IRVINE, CA--(Marketwired - Oct 21, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science Products are now hitting shelves in legal dispensaries within the State of California.

Clinical Ink Reports Record Contract Signings in Q3 - $16M in Bookings

Fri, 21 Oct 2016 09:30:00 EDT

PHILADELPHIA, PA and CAMBRIDGE, MA--(Marketwired - October 21, 2016) - Clinical Ink, the pioneering provider of eSource and patient engagement technologies for clinical trials, today announced record quarterly contract bookings of $16M in the third quarter of 2016.

Leveraging Smartphone Sensors to Measure Novel Health Outcomes, New Webinar Hosted by Xtalks

Fri, 21 Oct 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - October 21, 2016) - During an informative session, Dr. Bill Byrom, PhD, Senior Director of Product Innovation at ICON, Christian Gossens, PhD, MBA, Global Head of Early Development Workflows at F. Hoffman-La Roche Ltd and Professor Guillermo Sapiro, PhD, Electrical and Computer Engineering at Duke University will provide insight on three broad areas:

Scott Watson promoted to global chief creative officer at Ogilvy CommonHealth Worldwide

Fri, 21 Oct 2016 07:00:00 EDT

PARSIPPANY, NJ--(Marketwired - Oct 21, 2016) - Ogilvy CommonHealth Worldwide (, the health behavior change specialists of Ogilvy & Mather (, and a WPP company (NASDAQ: WPPGY) (, today announced Scott Watson has been elevated from EVP, chief creative officer of the NJ-based Ogilvy CommonHealth arm of Ogilvy CommonHealth Worldwide, to global chief creative officer of the entire network.

GeoVax HIV Vaccine Clinical Data Presented At HIVR4P Conference

Thu, 20 Oct 2016 14:30:00 EDT

Vaccine Shown to Induce Durable Functional Antibodies Against HIV

JDRF and the University of Toronto support research into a skin patch to prevent common, life-threatening risk of T1D

Thu, 20 Oct 2016 13:00:00 EDT

TORONTO, ON--(Marketwired - October 20, 2016) - JDRF and the University of Toronto are pleased to announce a $400,000 (USD) research grant to support the development of a skin [transdermal] patch to prevent hypoglycemia - a common, potentially life-threatening, risk for people living with type 1 diabetes (T1D).

Philips Healthcare, Medtronic Projected to Increase their Market Share Despite Competition and Reduced Healthcare Budgets

Thu, 20 Oct 2016 12:20:24 EDT

The patient monitoring market in Europe is expected to increase over the next several years to reach over EUR1.8 billion by 2022.

Popular Science Recognizes Probuphine as One of the 2016 "Best of What's New"

Thu, 20 Oct 2016 12:00:00 EDT

SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 20, 2016) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeuraT long-term, continuous drug delivery platform, is very pleased that Probuphine® has been recognized as one of the "12 Most Important Innovations of the Year" in the Health category in Popular Science's annual "Best of What's New" issue. Probuphine, a subdermal implant developed using Titan's proprietary ProNeura technology, was approved by the U.S. Food and Drug Administration in May 2016, becoming the first commercially available long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.

Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting

Thu, 20 Oct 2016 10:19:02 EDT

GERMANTOWN, MD--(Marketwired - Oct 20, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company, announced that Orgenesis CEO, Vered Caplan, will present at the T1D Exchange 4th Annual Meeting, which is being held at the Royal Sonesta Hotel in Boston, Massachusetts on October 21, 2016. Ms. Caplan will speak on the panel "Cellular and Biopharmaceutical Innovations."

The Obesity Society Honors Two U.S. Senators, Current and Emerging Leaders in Obesity Research with its 2016 Awards and Grants

Thu, 20 Oct 2016 09:54:59 EDT

Awardees will be recognized at ObesityWeek(SM) 2016, Oct. 31- Nov. 4, in New Orleans

Innovus Pharmaceuticals Supplement Androferti Improves Male Fertility, says top medical expert

Thu, 20 Oct 2016 09:30:00 EDT

When people have trouble conceiving, low sperm count or poor quality sperm is to blame in about 40% of the cases, but better diets and lifestyles, and a supplement from Innovus Pharmaceuticals called Androferti(R), can make a major difference

Research Out of Mexico Demonstrates Efficacy of Medical Marijuana's (MJNA) RSHO-X -- CFN Media

Thu, 20 Oct 2016 09:01:17 EDT

SEATTLE, WA--(Marketwired - Oct 20, 2016) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering new research, done in Mexico, that demonstrates the efficacy of Medical Marijuana, Inc.'s (OTC PINK: MJNA) RSHO-XT in the treatment of children with refractory epilepsy. The study, conducted by Dr. Carlos G. Aguirre Velazquez, reported 60% of 53 children treated with cannabidiol ("CBD") oil experienced a reduction in seizures, including 16% that were completely free of seizures and 51% that experienced a moderate to important improvement.

DigiPath Labs Validates New Extraction Technology

Thu, 20 Oct 2016 09:00:00 EDT

LAS VEGAS, NV--(Marketwired - Oct 20, 2016) - DigiPath Labs, a subsidiary of DigiPath, Inc. (OTCQB: DIGP), an independent cannabis testing lab and media firm, recently completed a successful validation of Fluid Management Systems' (FMS) pressure liquid extractor (PLEâ) for use across four different cannabis matrices.

iRemedy Healthcare Engages J. Streicher Capital as Investment Banker and Capital Markets Advisor

Thu, 20 Oct 2016 09:00:00 EDT

STUART, FL--(Marketwired - Oct 20, 2016) - iRemedy Healthcare, Inc., a SaaS business dedicated to enhancing practice profitability by providing the efficient distribution of products to and through healthcare organizations, today announced its engagement of J.Streicher Capital LLC as exclusive capital market advisor and placement agent for the Company.

Vaxil Announces Strategic Collaboration With Hadassah

Thu, 20 Oct 2016 09:00:00 EDT

Appointment of Top Hadassah Physician Scientist Professor Dr. Michael Shapira to Vaxil Scientific Advisory Board; Appointment of New CEO and Board Member

Sipp Industries Secures Partnership with Distinguished Brewery for Enhanced Production Capacity and Provides Update on Hemp and CBD Beer Initiatives

Thu, 20 Oct 2016 08:30:00 EDT

COSTA MESA, CA--(Marketwired - Oct 20, 2016) - Sipp Industries, Inc. (OTC PINK: SIPC), a multifaceted corporation specializing in technology, manufacturing, and distribution of commercial and consumer products is pleased to announce the Company has entered into a contractual agreement with a notable Colorado brewery. In anticipation of rising demand upon licensing, the Company has mobilized to strengthen the Company's production capacity.

Big Pharma's Getting Back Together with Medical Education

Thu, 20 Oct 2016 08:17:00 EDT

Nine out of ten global pharma teams provide funding for accredited CME

Pieris Announces Presentations at Upcoming R&D Conferences

Thu, 20 Oct 2016 08:00:00 EDT

BOSTON, MA--(Marketwired - October 20, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today presentations at two upcoming R&D conferences focused on immuno-oncology.

Moleculin Announces Reminder for Conference Call to Discuss Positive Developments Regarding Annamycin

Thu, 20 Oct 2016 08:00:00 EDT

Call Scheduled for Today to Include General Corporate Update

Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK

Thu, 20 Oct 2016 07:43:00 EDT

NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 20, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO):

Applying Sound Research Practices in Development of Medical Devices, a New Webinar Presented by Premier Research

Thu, 20 Oct 2016 07:15:00 EDT

TORONTO, ON--(Marketwired - October 20, 2016) - Medical device and diagnostic companies face greater demand to provide clinical evidence of product efficacy than ever before. Scrutiny not only from regulators, but from healthcare systems, physicians, and even patients, has prompted more device companies to perform clinical trials to meet regulatory requirements, differentiate their products, and improve the likelihood of commercial success. While these are similar to well-established pharma clinical studies, there are significant differences.

Using Synthetic Carbohydrates as Biological Targeting and Delivery Agents, New Webinar Hosted by Xtalks

Thu, 20 Oct 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - October 20, 2016) - In an informative session, industry expert Dr. Stewart Campbell, the Head of Business Development and Product Management, Carbohydrates from CordenPharma Switzerland/Woburn will discuss two areas with the goal of demonstrating that carbohydrates are indeed accessible and can be practical alternatives or adjuncts to more traditional targeting approaches. These two areas are:

SOTIO and NBE Therapeutics sign license agreement

Thu, 20 Oct 2016 05:57:29 EDT

PRAGUE, CZECH REPUBLIC--(Marketwired - Oct 20, 2016) -

Avita Medical's ReCell(R) devices now treating burns in South Africa and Benelux

Wed, 19 Oct 2016 20:15:24 EDT

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Oct 19, 2016) - Avita Medical Ltd, (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specialising in new treatments for wounds and skin defects, has identified distribution partners for its medical devices in South Africa and the three Benelux nations, the Company said today.

Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy

Wed, 19 Oct 2016 18:42:21 EDT

CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer

MEDIA ADVISORY: Canada's regenerative medicine community is in Whistler for fifth annual Till & McCulloch Meetings

Wed, 19 Oct 2016 18:02:24 EDT

TORONTO, ON--(Marketwired - October 19, 2016) - Canadian and international stem cell scientists and engineers will be in Whistler, British Columbia, October 24-26 to attend the Till & McCulloch Meetings (TMM), Canada's premier stem cell research event. Over 400 delegates are expected to attend. The agenda, featuring speakers and special events, is available here. Media are invited to register, free of charge, to monitor the scientific sessions.

Pegasystems to Announce Financial Results for the Third Quarter of 2016 via Conference Call and Webcast

Wed, 19 Oct 2016 16:05:00 EDT

CAMBRIDGE, MA--(Marketwired - October 19, 2016) - Pegasystems Inc. (NASDAQ: PEGA), the software company empowering customer engagement for the world's leading enterprises, today announced it will report financial results for the third quarter of 2016 on Wednesday, November 2, after market close.

Cannabis Science Negotiates an Additional 200 Acres in California and 100 Acres in Nevada for Indoor and Outdoor Grow and Production Operations, Keys for Large-Scale Nationwide Growth Strategy

Wed, 19 Oct 2016 11:03:01 EDT

IRVINE, CA--(Marketwired - Oct 19, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced they are in the process of negotiating for another couple of major new drug development property deals, this time for two properties, a 200-acre California property and a 100-acre property in Nevada.

DTRA and Navy Looking to Sharks for Warfighter Protection

Wed, 19 Oct 2016 10:47:58 EDT

FORT BELVOIR, VA--(Marketwired - October 19, 2016) - In new research funded by the Defense Threat Reduction Agency's Joint Science and Technology Office (JSTO) and performed by U.S. Naval Research Laboratory (NRL) scientists, shark antibodies are proving to offer new alternatives to chemical and biological threat detection and treatment tools. In an era of Department of Defense belt-tightening, the goal is to find more innovative, cost-effective approaches to protecting our warfighters.

Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies

Wed, 19 Oct 2016 09:00:00 EDT

Water solubility significantly improved more than 100-fold, enabling novel pharmaceutical applications

Big Pharma Expanding Patient Centricity through Top-Down Mandates

Wed, 19 Oct 2016 08:17:00 EDT

Study finds that two-thirds of Top 50 drug companies have a top-down patient-centric mandate in place

Kareo Launches Solution to Reduce Prescription Drug Costs for Patients

Wed, 19 Oct 2016 08:15:00 EDT

Pricing transparency and instant savings now available to independent physicians and their patients

Advanced Proteome Therapeutics Corporation Obtains Option to License Antibody Candidates and Collaborates With CCAB to Jointly Fund Research

Wed, 19 Oct 2016 08:00:00 EDT

VANCOUVER, BC--(Marketwired - October 19, 2016) - Advanced Proteome Therapeutics Corporation (APC) (TSX VENTURE: APC) (FRANKFURT: 0E8), a biopharmaceutical company dedicated to creating, developing, and commercializing innovative therapies, today announced that it has entered into an exclusive option agreement with the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto (UT). APC acquired an option to license validated antibody candidates suited for development of antibody-drug conjugates (ADCs) as potential treatments for cancer.

Adgero Biopharmaceuticals Expands Executive Management Team with Appointment of Laura Edgerly-Pflug as Vice President of Manufacturing Operations and Quality Control

Wed, 19 Oct 2016 07:30:00 EDT

Strengthening team with extensive experience in product and process development and scale-up from bench to commercial process

Xtalks Webinar to Discuss Patient Recruitment Strategies in Prodromal Alzheimer's Disease Clinical Trials

Wed, 19 Oct 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - October 19, 2016) - The webinar taking place on Tuesday, November 1 at 11:00 am. EDT will focus on strategic approaches to identify patients with Prodromal AD and connect them with a study site.

3D Signatures Included in Major Clinical Trial for Prostate Cancer

Wed, 19 Oct 2016 07:00:00 EDT

WINNIPEG, MB--(Marketwired - October 19, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce its participation in a major clinical trial for prostate cancer diagnosis and management known as PRECISE. This trial marks the Company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.

Nohla Therapeutics Signs Exclusive Supply Agreement With LifeSouth Community Blood Centers

Wed, 19 Oct 2016 05:30:00 EDT

SEATTLE, WA--(Marketwired - Oct 19, 2016) - Nohla Therapeutics Inc. (Nohla), a leading developer of universal donor cellular therapies for the treatment of patients with life threatening hematological disorders, announced today the signing of an exclusive supply agreement with LifeSouth Community Blood Centers in Gainesville, Florida. The agreement is specific to LifeSouth's cord blood banking program and will provide Nohla with fully qualified clinical grade cord blood units that will become the starting material for the Company's expanded hematopoietic stem and progenitor cell products.

U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell(R) in Life-Threatening Injuries

Tue, 18 Oct 2016 19:13:50 EDT

NORTHRIDGE, CA and PERTH, AUSTRALIA and LONDON, UNITED KINGDOM--(Marketwired - Oct 18, 2016) -

Breathtec BioMedical Announces Private Placement

Tue, 18 Oct 2016 17:08:00 EDT

VANCOUVER, BC--(Marketwired - Oct 18, 2016) - Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce that it intends to complete a non-brokered private placement offering of up to 13,333,333 units (the "Units") at a price of $0.075 per Unit for gross proceeds of up to $1,000,000 (the "Offering"). Each Unit will consist of one common share in the capital of the Company (a "Share") and one transferable common share purchase warrant (a "Warrant"), with each Warrant exercisable into one additional Share at a price of $0.15 for a period of three years from the date of closing.

Alcon, Abbott Medical Optics Lead Competitive Europe Interventional Ophthalmic Devices Market

Tue, 18 Oct 2016 13:20:40 EDT

The European market for diagnostic and interventional ophthalmic devices is expected to grow and exceed EUR1.9 billion by 2023

SuperSonic Imagine reports sales growth of +10% in Q3 2016

Tue, 18 Oct 2016 12:15:00 EDT

Solid growth in the United States; Further significant growth in Service sales

eTMF Market Expected to Grow Considerably Over the Next Three Years

Tue, 18 Oct 2016 10:30:00 EDT

Informing the pharmaceutical drug development, manufacturing and commercialization industry

MEDIA ALERT: Industry Leaders to Discuss How Technology Enables Better Patient Outcomes During Pega Healthcare Summit

Tue, 18 Oct 2016 10:00:00 EDT

CAMBRIDGE, MA--(Marketwired - October 18, 2016) - Pegasystems (NASDAQ: PEGA)

Kirk McPoyle Joins Clinical Ink as Chief Commercial Officer

Tue, 18 Oct 2016 09:41:45 EDT

WINSTON-SALEM, NC and PHILADELPHIA, PA--(Marketwired - October 18, 2016) - Clinical Ink®, the leading provider of eSource and mobile patient engagement technologies for clinical trials, announces the addition of Kirk McPoyle to its management team. He has joined Clinical Ink as the Chief Commercial Officer.

Advantis Corp. CEO Highlights Newest Company Developments

Tue, 18 Oct 2016 09:26:00 EDT

NEWPORT BEACH, CA--(Marketwired - Oct 18, 2016) - ADVANTIS CORPORATION (OTC PINK: ADVT) CEO, Chris Swartz, was recently interviewed by SmallCapVoice and is taking the time to further update shareholders on the current state of business.

Abattis (ATTBF): A Leader in Canada's Cannabis Testing Industry -- CFN Media

Tue, 18 Oct 2016 09:20:06 EDT

SEATTLE, WA--(Marketwired - Oct 18, 2016) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Canada's new cannabis testing regulations and why Abattis Bioceuticals' (OTCQB: ATTBF) Northern Vine Labs is well positioned in this burgeoning market.

Upcoming Webinar to Examine Pharmacogenetics in Pain Management and the Use of Pharmacogenomics Methodologies in the Pharmacovigilance Evaluation of Medicinal Products

Tue, 18 Oct 2016 08:17:27 EDT

TORONTO, ON--(Marketwired - October 18, 2016) - In this presentation Dr. Lynn Webster, Vice President of Scientific Affairs (Early Development Services), and Michael Marschler, Director of Safety and Risk Management, both from PRA Health Sciences, will discuss how pharmacogenetics can be integrated in clinical trials. The speakers will also outline post-marketing settings to achieve a personalized therapy and how considering missing information (potential risk(s)) of genomic variations can help to identify risk minimization measures to greatly reduce the risk of side effects and significantly increase the therapeutic benefit to the patients.

Drug Companies' Launch Sequencing Strategy Influences Approval Team Structure

Tue, 18 Oct 2016 08:17:00 EDT

75% of Pharma Companies have an Ad Hoc Committee Responsible for Launch Sequencing

Harnessing the Power of mHealth for New, Better Data and Improved Patient Engagement, New Webinar Hosted by Xtalks

Tue, 18 Oct 2016 08:15:45 EDT

TORONTO, ON--(Marketwired - October 18, 2016) - In this webinar, Lewis Millen, Operational Intelligence Leader from Roche Products Limited and Matt Kibby, President of BBK Worldwide will discuss how mHealth can improve patient recruitment, retention and engagement to create a better overall patient experience. They will outline how mHealth helps remove key communication barriers and improve multi-stakeholder collaboration and streamline recruitment and engagement tactics -- all while reducing study inefficiencies and overall costs. The live session will take place Friday, October 28, 2016 at 12pm EDT.

Functional Brain Imaging Using MRI: An Emerging Tool for Drug Development and Clinical Trials, Upcoming Webinar Hosted by Xtalks

Tue, 18 Oct 2016 08:13:52 EDT

TORONTO, ON--(Marketwired - October 18, 2016) - During a live presentation on Friday, October 28, 2016, Dr. Maria Laura Blefari, Biomedical Engineer from WorldCare Clinical and Dr. Mykol Larvie, Physician, Department of Radiology, Director of Molecular Neuroimaging, Massachusetts General Hospital will extend their expertise and provide:

Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV(R) (telavancin), Including Ongoing TOUR(TM) Observational Patient Registry, at IDWeek 2016

Tue, 18 Oct 2016 08:05:00 EDT

First Presentation of TOUR Data Highlights Real World Experience with VIBATIV in Range of Difficult-to-Treat Infections; Additional VIBATIV Presentations Report Results from Retrospective Analysis in Osteomyelitis Patients and Multiple Studies Evaluating in vitro Potency in Challenging Pathogens Compared to Other Commercialized Antibiotics

Aphria and MassRoots Partner in One of First International Collaborations between Cannabis Companies

Tue, 18 Oct 2016 08:00:00 EDT

LEAMINGTON, ONTARIO--(Marketwired - Oct. 18, 2016) - Aphria Inc. ("Aphria" or the "Company") (TSX VENTURE:APH) (OTCQB:APHQF) one of the leading Canadian licensed producers of medical cannabis, and MassRoots, Inc., one of the largest technology platforms for the cannabis industry, are pleased to announce they have entered into one of the first international partnerships between cannabis companies. Under the terms of the agreement, MassRoots will help build awareness of the Aphria brand amongst its Canadian userbase. Aphria will compensate MassRoots a cash fee (in U.S. dollars) it refers.

Biomerica Announces First Quarter Fiscal 2017 Financial Results, Sales Increase Over Prior Year

Tue, 18 Oct 2016 07:57:00 EDT

IRVINE, CA--(Marketwired - October 18, 2016) - Biomerica, Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic products, today reported net sales of $1,410,110 for the three months ending August 31, 2016, compared to $1,286,993 for the same period in the previous year, an increase of nearly 10%.

Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A

Tue, 18 Oct 2016 07:45:00 EDT

NEW YORK, NY, and CLEVELAND, OH--(Marketwired - October 18, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical- stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona's lead gene therapy program ABO-102 for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death in children.

Endonovo Therapeutics Announces Registration Statement on Form S-1 has been Declared Effective

Tue, 18 Oct 2016 07:05:00 EDT

Financing will Allow Endonovo to Conduct Pre-Clinical Studies on Liver Inflammation and Regeneration Using the Company's Non-Invasive Electroceutical Platform

Medifirst Solutions Announces Update Regarding Sales and Operations

Mon, 17 Oct 2016 13:00:53 EDT

FREEHOLD, NJ--(Marketwired - Oct 17, 2016) -  MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") would like to update shareholders regarding recent company developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.

Pegasystems and MCG Health Partner to Integrate Industry-Leading Chronic Care Standards in Pega Care Management Application

Mon, 17 Oct 2016 10:00:00 EDT

Partnership Will Enable Care Management Teams to Drive Better Health Outcomes for Patients

3D Signatures Letter to Shareholders

Mon, 17 Oct 2016 09:30:00 EDT

WINNIPEG, MB--(Marketwired - October 17, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS"), a personalized medicine company developing precision clinical tests using a proprietary software platform based on three-dimensional analysis of chromosomal signatures, is pleased to provide a letter to shareholders providing guidance and insight into the Company's milestones over the coming year. Jason Flowerday, the Company's CEO, is excited to report on the company's early progress and to provide a roadmap to commercialization.

CBIS Breaking News: Polling by UC Berkeley Recently Shows Nearly 2:1 Voting Support Passing Proposition 64 in California; CNET Reports: Virgin's Sir Richard Branson to Cannabis Advocates: Fight to Legalize it

Mon, 17 Oct 2016 09:12:09 EDT

More Historic Days Ahead, November the 8th: Voters in Five States -- California, Arizona, Massachusetts, Maine and Nevada -- Will Decide to Fully Legalize and Regulate Marijuana

Pharmaceutical & Healthcare Leaders Collaborate to Improve the Patient Journey

Mon, 17 Oct 2016 09:01:00 EDT

End-to-End Self-Injection Platform to Improve Adherence Showcased at 2016 PDA Universe of Pre-filled Syringes and Injection Devices

Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology

Mon, 17 Oct 2016 09:00:00 EDT

MOUNTAIN VIEW, CA--(Marketwired - October 17, 2016) - Amunix is pleased to announce that Versartis Inc. (NASDAQ: VSAR) has been granted approval in Japan by the PMDA to initiate enrollment for its Phase 3 study of somavaratan (XTENylated recombinant growth hormone) in pediatric patients with growth hormone deficiency (GHD).

Breathtec BioMedical Provides Corporate Overview

Mon, 17 Oct 2016 08:30:00 EDT

Company Offers Update of Events and Outlook for Near Term Opportunity

Ritter Pharmaceuticals Concludes Last Patient Visit of Its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance

Mon, 17 Oct 2016 08:30:00 EDT

LOS ANGELES, CA--(Marketwired - Oct 17, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.

Critical Outcome Technologies Awards Stock Options

Mon, 17 Oct 2016 08:30:00 EDT

LONDON, ON and BOSTON, MA--(Marketwired - October 17, 2016) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that 1,691,427 stock options were awarded to directors and employees under the Company's Stock Option Plan on October 13, 2016. The award to directors was made as a retainer for their services to the Board and its committees for the upcoming year. The award to employees was made on a discretionary basis for their efforts during the past year. The options have a five year life with 25% vesting occurring at the end of each quarter during the first year following the grant date. The exercise price is $0.52 and represents the closing price of the Company's common shares on the TSX Venture Exchange on October 12, 2016, the last trading day prior to the award date.

RespireRx Pharmaceuticals Inc. to Present at the BIO Investor Forum on Tuesday, October 18, 2016 at the St. Francis Hotel in San Francisco, California

Mon, 17 Oct 2016 08:15:00 EDT

GLEN ROCK, NJ--(Marketwired - Oct 17, 2016) - RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company's President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the BIO Investor Forum on Tuesday, October 18, 2016 at 11:00 A.M. Pacific Time. The Forum is sponsored by the Biotechnology Innovation Organization and is scheduled for Tuesday and Wednesday, October 18 and 19, 2016. Dr. Manuso will be available for one-on-one meetings with Forum attendees on both days.

Hisamitsu America, the Global Leader of Topical Pain Patches, Introduces the Salonpas(R) Lidocaine 4% Pain Relieving Gel-Patch

Mon, 17 Oct 2016 08:00:00 EDT

FLORHAM PARK, NJ--(Marketwired - Oct 17, 2016) - Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the Salonpas® Pain Relief Patch which is the one and only OTC pain patch that is FDA approved and clinically proven, maintains their commitment to providing industry leading, topical analgesic solutions with the launch of the new Salonpas® Lidocaine 4% Pain Relieving Gel-Patch. The patch features the maximum strength lidocaine available without a prescription, using a proprietary hydro-gel technology to sooth aggravated nerves.

Moleculin Announces Conference Call to Discuss Positive Developments Regarding Annamycin

Mon, 17 Oct 2016 08:00:00 EDT

Call Scheduled for This Thursday, October 20th to Include General Corporate Update

ICH E6(R2) Benchmark Survey: Essential Elements of Compliant CRO Oversight, New Webinar Hosted by Xtalks

Mon, 17 Oct 2016 07:30:00 EDT

TORONTO, ON--(Marketwired - October 17, 2016) - In this presentation, Bruno Gagnon, B Pharm, MSc, Clinical Intelligence Expert and Matt McKinney, Clinical Intelligence Expert, Comprehend Systems will showcase the results of Comprehend's 2016 ClinOps ICH E6(R2) survey and its impact on the CRO/Sponsor relationship. The live broadcast will take place on Thursday, October 27, 2016 at 2pm EDT.